Published in Virus Weekly, October 20th, 1997
In a randomized controlled Phase III study of 704 chronic Hepatitis C patients treated with either Intron A (Schering Plough, Kenilworth, New Jersey) or Infergen (Amgen Inc. Thousand Oaks, California), the Superquant HCV assay was used to assess changes in viral concentrations over the course of treatment and six months after stopping...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly